Cardlytics Inc Is Being Looked Into For Violating Securities Regulations And Stakeholders Are Urged To Spearhead The Investigation
Rhea-AI Summary
The Schall Law Firm, a national shareholder rights litigation firm, is investigating Cardlytics, Inc. (NASDAQ:CDLX) for potential securities law violations. The investigation centers on whether Cardlytics issued false or misleading statements or failed to disclose important information to investors. The company's Q2 2024 financial results, released on August 7, 2024, significantly missed projections made just three months earlier. Cardlytics attributed the shortfall to "fast-paced changes to our technology platform," but when questioned by analysts, management admitted that these technology issues had been known for "a quarter or two." The firm encourages affected shareholders to participate in the investigation and offers free consultations to discuss investor rights.
Positive
- None.
Negative
- Cardlytics (CDLX) is under investigation for potential securities law violations
- Q2 2024 financial results significantly missed projections made three months prior
- Company admitted to knowing about technology issues for 'a quarter or two' before disclosing
- Potential false or misleading statements to investors regarding technology initiatives
News Market Reaction – CDLX
On the day this news was published, CDLX declined 3.06%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cardlytics claimed to the market that its technology initiatives were "really paying off." But the Company's Q2 2024 financial results, released on August 7, 2024, significantly missed its projections from just three months prior. The Company blamed the shortfall on "fast-paced changes to our technology platform." When questions by analysts, the Company's management admitted that its technology issues had been known for "a quarter or two."
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
What is the Schall Law Firm investigating Cardlytics (CDLX) for?
When did Cardlytics (CDLX) release its Q2 2024 financial results?
What reason did Cardlytics (CDLX) give for missing its financial projections in Q2 2024?
How long had Cardlytics (CDLX) known about the technology issues before disclosing them?
